Journal of General Internal Medicine

, Volume 33, Issue 1, pp 34–41 | Cite as

Overtreatment and Deintensification of Diabetic Therapy among Medicare Beneficiaries

  • Matthew L. Maciejewski
  • Xiaojuan Mi
  • Jeremy Sussman
  • Melissa Greiner
  • Lesley H. Curtis
  • Judy Ng
  • Samuel C. Haffer
  • Eve A. Kerr
Original Research

Abstract

Background

Deintensification of diabetic therapy is often clinically appropriate for older adults, because the benefit of aggressive diabetes treatment declines with age, while the risks increase.

Objective

We examined rates of overtreatment and deintensification of therapy for older adults with diabetes, and whether these rates differed by medical, demographic, and socioeconomic characteristics.

Design, Subjects, and Main Measures

We analyzed Medicare claims data from 10 states, linked to outpatient laboratory values to identify patients potentially overtreated for diabetes (HbA1c < 6.5% with fills for any diabetes medications beyond metformin, 1/1/2011–6/30/2011). We examined characteristics associated with deintensification for potentially overtreated diabetic patients. We used multinomial logistic regression to examine whether patient characteristics associated with overtreatment of diabetes differed from those associated with undertreatment (i.e. HbA1c > 9.0%).

Key Results

Of 78,792 Medicare recipients with diabetes, 8560 (10.9%) were potentially overtreated. Overtreatment of diabetes was more common among those who were over 75 years of age and enrolled in Medicaid (p < 0.001), and was less common among Hispanics (p = 0.009). Therapy was deintensified for 14% of overtreated diabetics. Appropriate deintensification of diabetic therapy was more common for patients with six or more chronic conditions, more outpatient visits, or living in urban areas; deintensification was less common for those over age 75. Only 6.9% of Medicare recipients with diabetes were potentially undertreated. Variables associated with overtreatment of diabetes differed from those associated with undertreatment.

Conclusions

Medicare recipients are more frequently overtreated than undertreated for diabetes. Medicare recipients who are overtreated for diabetes rarely have their regimens deintensified.

KEY WORDS

Medicare beneficiary diabetes potential overtreatment deintensification 

Notes

Acknowledgements

We thank the editor and two reviewers for helpful comments. The research in this article was supported by the Centers for Medicare & Medicaid Services under contract number HHSM-500-2014-00442G with the National Committee for Quality Assurance. This work was also supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs, and Dr. Maciejewski was also supported by a Research Career Scientist award from the Department of Veterans Affairs (RCS 10-391). The National Committee for Quality Assurance and the Centers for Medicare & Medicaid Services provided feedback on interpretation of the data when the manuscript was reviewed and approved, but had no role in the design, conduct, collection, management, or analysis of the data. This work was presented at the 2017 AcademyHealth Annual Research Meeting. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, Duke University, the National Committee for Quality Assurance, the Centers for Medicare & Medicaid Services, or the US Department of Health and Human Services. We acknowledge helpful review by Sarah Scholle, Michael Barr, and Mary Barton at the National Committee for Quality Assurance.

Compliance with Ethical Standards

Conflict of Interest

Dr. Maciejewski has received institutional grants from the VA HSR&D, the Agency for Healthcare Research and Quality, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Cancer Institute, and an institutional contract from the Centers for Medicare & Medicaid Services; and reports ownership of Amgen stock due to his spouse’s employment. Dr. Maciejewski received honoraria for speaking at a workshop held at the University of Alabama-Birmingham. Dr. Sussman has received research support from VA HSR&D in the form of a career development award. Dr. Curtis has received research support from the Agency for Healthcare Research and Quality, the Patient-Centered Outcomes Research Institute, Boston Scientific, Bristol-Myers Squibb, GE Healthcare, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, and Novartis. Dr. Kerr has received research support from VA HSR&D to examine deintensification of medical services. All other authors declare that they have no conflict of interest.

References

  1. 1.
    Kerr EA, Hofer TP. Deintensification of Routine Medical Services: The Next Frontier for Improving Care Quality. JAMA Intern Med. 2016;176(7):978-980.CrossRefPubMedGoogle Scholar
  2. 2.
    Canada Choosing Wisely website. http://www.choosingwiselycanada.org. Accessed 5 March 2017.
  3. 3.
    UK Choosing Wisely website. http://www.choosingwisely.co.uk/. Accessed 5 March 2017.
  4. 4.
    Levinson W, Kallewaard M, Bhatia RS, et al. 'Choosing Wisely': a growing international campaign. BMJ Qual Saf 2015;24(2):167-174.CrossRefPubMedGoogle Scholar
  5. 5.
    AGS Choosing Wisely Workgroup. American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc 2013;61(4):622-631.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus, Moreno G, Mangione CM, Kimbro L, Vaisberg E. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. J Am Geriatr Soc 2013;61(11):2020-2026.CrossRefGoogle Scholar
  7. 7.
    National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations. Accessed 1 December 2018.
  8. 8.
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865.Google Scholar
  9. 9.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.Google Scholar
  10. 10.
    ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-2572.CrossRefGoogle Scholar
  11. 11.
    Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-2559.CrossRefGoogle Scholar
  12. 12.
    Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150(11):803-808.CrossRefPubMedGoogle Scholar
  13. 13.
    Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA. 2016;315(10):1034-1045.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157(15):1681-1686.CrossRefPubMedGoogle Scholar
  15. 15.
    McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012;35(9):1897-1901.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract 2013;19(5):792-799.CrossRefPubMedGoogle Scholar
  17. 17.
    Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med 2014;174(2):259-268.CrossRefPubMedGoogle Scholar
  18. 18.
    Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015;175(3):356-362.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sussman JB, Kerr EA, Saini SD, et al. Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus. JAMA Intern Med 2015;175(12):1942-1949.CrossRefPubMedGoogle Scholar
  20. 20.
    Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care Apr 2015;38(4):588-595.PubMedPubMedCentralGoogle Scholar
  21. 21.
    McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND. Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Intern Med 2016;176(7):969-978.Google Scholar
  22. 22.
    Muller N, Khunti K, Kuss O, et al. Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta Diabetol Feb 2017;54(2):209-214.CrossRefPubMedGoogle Scholar
  23. 23.
    Penfornis A, Fiquet B, Blickle JF, Dejager S. Potential glycemic overtreatment in patients >/=75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study. Diabetes Metab Syndr Obes 2015;8:303-313.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Ayanian JZ, Landon BE, Newhouse JP, Zaslavsky AM. Racial and ethnic disparities among enrollees in Medicare Advantage plans. N Engl J Med 2014;371(24):2288-2297.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bonds DE, Zaccaro DJ, Karter AJ, Selby JV, Saad M, Goff DC, Jr. Ethnic and racial differences in diabetes care: The Insulin Resistance Atherosclerosis Study. Diabetes Care 2003;26(4):1040-1046.CrossRefPubMedGoogle Scholar
  26. 26.
    Heisler M, Smith DM, Hayward RA, Krein SL, Kerr EA. Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care 2003;41(11):1221-1232.CrossRefPubMedGoogle Scholar
  27. 27.
    Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287(19):2519-2527.CrossRefPubMedGoogle Scholar
  28. 28.
    Kirk JK, D'Agostino RB, Jr., Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2006;29(9):2130-2136.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hammill BG, Curtis LH, Qualls LG, Hastings SN, Wang V, Maciejewski ML. Linkage of Laboratory Results to Medicare Fee-for-Service Claims. Med Care 2015;53(11):974-979.CrossRefPubMedGoogle Scholar
  30. 30.
    Gorina Y, Kramarow EA. Identifying chronic conditions in Medicare claims data: evaluating the Chronic Condition Data Warehouse algorithm. Health Serv Res 2011;46(5):1610-1627.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Huang ES. Potential Overtreatment of Older, Complex Adults With Diabetes. JAMA. 2015;314(12):1280-1281.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care 2011;34 Suppl 1:S11-61.CrossRefPubMedCentralGoogle Scholar
  33. 33.
    National Committee for Quality Assurance. HEDIS 1999, Volume 2: Technical Specifications for Health Plans. Washington DC: National Committee for Quality Assurance; 1999.Google Scholar
  34. 34.
    Ajmera M, Raval A, Zhou S, et al. A Real-World Observational Study of Time to Treatment Intensification Among Elderly Patients with Inadequately Controlled Type 2 Diabetes Mellitus. J Manag Care Spec Pharm 2015;21(12):1184-1193.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    US Department of Agriculture ERS. Rural urban commuting area codes. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/. Accessed 31 March 2011.
  36. 36.
    Center WWAMI Rural Health Research Center. RUCA data: using RUCA data. http://depts.washington.edu/uwruca/ruca-data.php. Accessed 31 March 2011.
  37. 37.
    Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35(12):2650-2664.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    American Diabetes Association. Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes 2016;34(1):3-21.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Society of General Internal Medicine (outside the USA) 2017

Authors and Affiliations

  • Matthew L. Maciejewski
    • 1
    • 2
  • Xiaojuan Mi
    • 3
  • Jeremy Sussman
    • 4
    • 5
  • Melissa Greiner
    • 3
  • Lesley H. Curtis
    • 2
    • 3
  • Judy Ng
    • 6
  • Samuel C. Haffer
    • 7
  • Eve A. Kerr
    • 4
    • 5
  1. 1.Center for Health Services Research in Primary CareDurham Veterans Affairs Medical CenterDurhamUSA
  2. 2.Division of General Internal Medicine, Department of MedicineDuke University Medical CenterDurhamUSA
  3. 3.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA
  4. 4.Center for Clinical Management ResearchAnn Arbor Veterans Affairs Medical CenterAnn ArborUSA
  5. 5.Department of Internal Medicine and Institute for Healthcare Policy and InnovationUniversity of Michigan Medical SchoolAnn ArborUSA
  6. 6.National Committee for Quality AssuranceWashingtonUSA
  7. 7.Office of Minority Health, U.S. Centers for Medicare & Medicaid ServicesBaltimoreUSA

Personalised recommendations